Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Lab and Cosmetic PCLBKK:BLC +1.00%64 3-Year EBITDA Growth Rate is 9.10% as of Jun. 2026, which is 51% below its 10-year median of 18.75. GuruFocus rates BKK:BLC with a GF Score™ of 64/100 and a GF Value™ of ฿4.70 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,677 Consumer Packaged Goods companies, Bangkok Lab and Cosmetic PCL ranks better than 52.24% on this metric.
During the past 12 months, Bangkok Lab and Cosmetic PCL's average EBITDA Per Share Growth Rate was -21.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bangkok Lab and Cosmetic PCL was 28.40% per year. The lowest was 9.10% per year. And the median was 18.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bangkok Lab and Cosmetic PCL 3-Year EBITDA Growth Rate Related Terms
BKK:BLC vs PG, CL, EL: 3-Year EBITDA Growth Rate Comparison
For the Household & Personal Products subindustry, Bangkok Lab and Cosmetic PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Lab and Cosmetic PCL 3-Year EBITDA Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bangkok Lab and Cosmetic PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bangkok Lab and Cosmetic PCL's 3-Year EBITDA Growth Rate falls into.
Bangkok Lab and Cosmetic PCL 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.10% mean?
Bangkok Lab and Cosmetic PCL (BKK:BLC) has a 3-Year EBITDA Growth Rate of 9.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bangkok Lab and Cosmetic PCL and its competitors. This is 51% below median its historical median of 18.75. Over the past decade, Bangkok Lab and Cosmetic PCL's 3-Year EBITDA Growth Rate has ranged from 9.10 to 28.40. According to the industry distribution chart, Bangkok Lab and Cosmetic PCL ranks #801 out of 1677 companies in the Consumer Packaged Goods industry, placing it in the top 47.8%.
Is Bangkok Lab and Cosmetic PCL's 3-Year EBITDA Growth Rate too high?
Bangkok Lab and Cosmetic PCL's current 3-Year EBITDA Growth Rate of 9.10% is 51% below median its 10-year median of 18.75. Over the past 10 years, this metric has ranged from a low of 9.10 to a high of 28.40. The Consumer Packaged Goods industry median 3-Year EBITDA Growth Rate is 8.00. Bangkok Lab and Cosmetic PCL's value of 9.10% is 13.8% above this industry median. Based on the distribution chart, Bangkok Lab and Cosmetic PCL ranks #801 out of 1677 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Bangkok Lab and Cosmetic PCL has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bangkok Lab and Cosmetic PCL's 3-Year EBITDA Growth Rate compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Bangkok Lab and Cosmetic PCL ranks #801 out of 1677 companies for 3-Year EBITDA Growth Rate. This puts Bangkok Lab and Cosmetic PCL in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.00. Bangkok Lab and Cosmetic PCL's value of 9.10% is 13.8% above this benchmark. Historically, Bangkok Lab and Cosmetic PCL's own 3-Year EBITDA Growth Rate has ranged from 9.10 to 28.40 over the past decade. While the company's 10-year median is 18.75 vs. the industry median of 8.00, Bangkok Lab and Cosmetic PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Consumer Packaged Goods company?
The median 3-Year EBITDA Growth Rate among Consumer Packaged Goods companies is 8.00, based on 1,677 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Lab and Cosmetic PCL's current 3-Year EBITDA Growth Rate of 9.10% is 13.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bangkok Lab and Cosmetic PCL and its competitors. For the Consumer Packaged Goods industry, the median 3-Year EBITDA Growth Rate is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Lab and Cosmetic PCL's current 3-Year EBITDA Growth Rate is 9.10%, which is 51% below median its own 10-year median of 18.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Lab and Cosmetic PCL stock overvalued right now?
Based on GuruFocus' analysis, Bangkok Lab and Cosmetic PCL (BKK:BLC) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿4.70, compared to a current price of ฿4.04 — trading 14% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.10%, which is 51% below median its 10-year median of 18.75 and 13.8% above the Consumer Packaged Goods industry median of 8.00. Bangkok Lab and Cosmetic PCL's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bangkok Lab and Cosmetic PCL (BKK:BLC), the current 3-Year EBITDA Growth Rate is 9.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bangkok Lab and Cosmetic PCL (BKK:BLC) Overvalued in 2026?
Based on GuruFocus' analysis, Bangkok Lab and Cosmetic PCL stock appears to be undervalued.
The current stock price of ฿4.04 is trading 14% below its estimated GF Value™ of ฿4.70.
GuruFocus considers Bangkok Lab and Cosmetic PCL to be Modestly Undervalued.
Key valuation signals for BKK:BLC:
3-Year EBITDA Growth Rate: 9.10% (51% below median its 10-year median of 18.75)
GF Value™: ฿4.70 vs. price of ฿4.04 (14% below fair value)
Industry Position: 13.8% above the Consumer Packaged Goods median (#801 of 1677)
No single metric tells the full story. See the BKK:BLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bangkok Lab and Cosmetic PCL are one of Thailand's comprehensive healthcare solutions groups. The principal activities of the Group are the manufacturing and distributing of pharmaceuticals and medicinal chemical products for human and animal It operates in a single line of business, namely pharmaceuticals and medicinal chemical products, The Group derives revenue from sales of goods and rendering of services.
64GF Score
Get the complete analysis for BKK:BLC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BLC has been successfully added to your 
